For example, most (chronic) hematopoietic neoplasms exhibiting the FIP1L1-PDGFRA fusion protein are responsive to treatment with imatinib [105–108] whereas this is not the case in patients with a FGFR1-mutated malignancy. Here, FGFR1 is linked to hematopoietic and lymphoid cell neoplasm.